COMPASS Pathways stock has delivered a very strong 214.4% gain over the past year, yet the valuation checks and current market multiples point to a more cautious picture rather than a clear bargain.

• The 214.4% one year return highlights how quickly sentiment has shifted around COMPASS Pathways and raises the bar for what needs to go right from here for the stock to justify that move.
• Heavy investment in late stage psilocybin therapy development can support long term revenue potential, while the current loss making profile and ongoing funding needs may weigh on how investors price the stock.
• A mixed value score of 3 out of 6 suggests COMPASS Pathways does not stand out as clearly cheap or clearly expensive on the broader checks.

The stock's next move may depend on whether recent gains have already priced in the key milestones that COMPASS Pathways still needs to deliver.

Does COMPASS Pathways Look Pricey on Book Value?

P/B is often a useful anchor for pre-revenue biotechs like COMPASS Pathways because it compares the stock price to the equity base that funds its research pipeline.

COMPASS Pathways trades at a P/B of 21.6x, which is far above the broader biotech industry average of 2.5x and still above a peer group average of 41.7x that already tends to capture higher risk, higher expectation stocks. This kind of premium suggests investors are putting a lot of weight on the potential of the psilocybin therapy platform rather than the current balance sheet.

The recent Q2 2026 loss, which was wider than analysts expected, has not stopped the market from assigning this rich P/B multiple. Instead, the higher ratio reflects strong enthusiasm for COMPASS Pathways and its pipeline despite the current loss making profile. On this P/B yardstick, the stock appears clearly more expensive than the typical biotech peer.

The COMPASS Pathways Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the COMPASS Pathways valuation puzzle leaves off. They spell out which assumptions about COMPASS Pathways' future growth, margins and earnings need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Each Narrative ties a fair value estimate to a specific set of potential catalysts and risks so you can track which storyline appears to be unfolding over time.

The community sits on two very different scenarios for COMPASS Pathways, with one camp focused on upside from COMP360 and the other on execution and funding risks.

Bull case: 45% undervalued

"Years of preparatory work with strategic collaborations, medical science liaisons and interventional centers, combined with the decision to pull forward marketing, sales force design and market access activities, positions COMPASS to convert any approval into earlier prescription volume, which would flow through to revenue and potentially improve net margins as fixed commercial costs are absorbed..."

Bear case: roughly fairly valued

"Although there are around 6,000 interventional psychiatry sites that can administer multi hour treatments like Spravato, real world adoption of psilocybin assisted therapy may be gradual if provider workflows, staffing models and reimbursement policies adjust slowly, which could restrain treatment volumes, revenue per site and operating leverage for several years..."

Do you think there's more to the story for COMPASS Pathways? Head over to our Community to see what others are saying!

The Bottom Line

For COMPASS Pathways, current market multiples point to a stock that already reflects a lot of optimism about the psilocybin therapy platform. The mixed valuation checks indicate that this is not a clear value opportunity, even if the story is appealing. The key question from here is whether COMPASS Pathways can convert its clinical and regulatory milestones into a commercial model that supports the premium investors are currently willing to pay.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.